RELATIONSHIP BETWEEN G-CSF AND HYPERLEUKOCYTOSIS INPATIENTS WITH APL AFTER TREATMENT WITH ALL-TRANSRETINOIC ACID

被引:4
|
作者
姜国胜
唐天华
孙关林
张玉昆
吴文
吴维礼
任海泉
赵良玉
机构
关键词
G-CSF; hyperlcucocytosis; Acutepromyelocytic leukemia;
D O I
暂无
中图分类号
R733.71 [急性白血病];
学科分类号
100214 ;
摘要
Objective: To detect the G-CSF effect and itsmechanism in hyperleucocytosis of patients with APLafter treatment with all-trans retinoic acid (ATRA).Methods: MTT method was used to measure theproliferation of HL-60 cells or primary APL cells.cDNA-mRNA dot blot hybridization was used to detectthe c-myc gene expression level of HL-60 cells afterATRA treatment. Cycle shift of HL-60 cells wasmeasured by flow cytometric Analysis. Results: ATRAcould inhibit obviously in vitro the proliferation of HL60 cells of primary APL cells. The G0/G, ratio of HL-60at 24 hours or 96 hours post-treatment with ATRA wasincreased, proliferation of HL-60 cells at the same timewas promoted obviously under the condition of rhGCSE C-myc gene expression was analyzed by dot blothybridization; its expression levels of 8, 24 or 96 hoursin culture with ATRA separately were higheF, low, highor lower as compared with each other. Conclusion: GCSF plays an important role in hyperleucocytosis ofpatients with APL after treatmellt with ATRA.
引用
收藏
页码:3 / 5
页数:4
相关论文
共 50 条
  • [1] Acute promyelocytic leukemia in children: Treatment with all-transretinoic acid
    Maschan, AA
    Klebanova, NG
    Myakova, NV
    Tiganova, OA
    Timakov, AM
    Samochatova, EV
    GEMATOLOGIYA I TRANSFUZIOLOGIYA, 1996, 41 (02): : 43 - 45
  • [2] VARIATION OF SERUM G-CSF LEVEL IN APL TREATED WITH ALL-TRANS RETINOIC ACID
    姜国胜
    孙关林
    唐天华
    吴文
    周荣富
    邹维礼
    李秀松
    沈志祥
    张芬琴
    陈钰
    王振义
    ChineseJournalofCancerResearch, 1999, (02) : 131 - 135
  • [3] Disseminated Exfoliative Dermatitis Associated with All-Transretinoic Acid in the Treatment of Acute Promyelocytic Leukemia
    Ipek, Yonal
    Hulya, Dogru
    Melih, Aktan
    CASE REPORTS IN MEDICINE, 2012, 2012
  • [4] Prognostic value of immunophenotype analysis in patients with acute promyelocytic leukemia (APL) treated with all-transretinoic acid and anthracyclin monochemotherapy.
    Montesinos, Pau
    Rivas, Concepcion
    Rayon, Consuelo
    Vellenga, Edo
    de la Sema, Javier
    Bergua, Juan
    Parody, Ricardo
    Brunet, Salud
    Milone, Gustavo
    Sanz, Miguel
    BLOOD, 2006, 108 (11) : 664A - 664A
  • [5] Treatment of severe immune neutropenia with ALL-transretinoic acid (ATRA) and autologous PBSC transplantation.
    Ovilla, R
    Rubio, ME
    Sosa, RE
    Arana, RM
    Borbolla, JR
    BLOOD, 1999, 94 (10) : 404B - 404B
  • [6] Use of all-transretinoic acid (ATRA) plus arsenic trioxide (ATO) to eliminate or minimize use of chemotherapy (CT) in untreated acute promyelocytic leukemia (APL).
    Estey, EH
    Garcia-Manero, G
    Ferrajoli, A
    Faderl, S
    Verstovsek, S
    Kantarjian, H
    BLOOD, 2004, 104 (11) : 115A - 115A
  • [7] All-transretinoic Acid (ATRA) Treatment-related Pancarditis and Severe Pulmonary Edema in a Child With Acute Promyelocytic Leukemia
    Isik, Pamir
    Cetin, Ilker
    Tavil, Betul
    Azik, Fatih
    Kara, Abdurrahman
    Yarali, Nese
    Tunc, Bahattin
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2010, 32 (08) : E346 - E348
  • [8] Is There Still a Role for Low-Dose All-Transretinoic Acid in the Treatment of Acute Promyelocytic Leukemia in the Arsenic Trioxide Era?
    Carlos Jaime-Perez, Jose
    Judith Gonzalez-Leal, Xitlaly
    Andrea Pinzon-Uresti, Monica
    Gomez-De Leon, Andres
    Cantu-Rodriguez, Olga G.
    Gutierrez-Aguirre, Homero
    Gomez-Almaguer, David
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 (12): : 816 - 819
  • [9] Does all-transretinoic acid (ATRA) have a role in non-APL acute myeloid leukaemia?: Results from 1666 patients in three MRC trials.
    Burnett, AK
    Milligan, D
    Hills, RK
    Goldstone, AH
    Prentice, AG
    Wheatley, K
    Webb, DC
    Gibson, B
    BLOOD, 2004, 104 (11) : 497A - 497A
  • [10] Is there a relationship between G-CSF response to conditioning regimen and engraftment after bone marrow transplantation
    M Özcan
    M Beksaç
    Bone Marrow Transplantation, 1998, 21 : 533 - 534